Breast Cancer Rates Decrease
in White Affluent Women over 50

Dr. C.W. Randolph Unveils the Hidden “Money-Hormone-Choice” Variable

Only white, affluent women over 50 are showing a decline in breast cancer rates across the country, according to a new study published in the American Journal of Public Health. Harvard researchers analyzed data evidencing a decline in breast cancer rates across the country and discovered this startling fact. No such decrease in the number of diagnosed breast cancers was evident among African American, Hispanic or Asian/Pacific Islander women. The researchers attributed the decrease in this racial, socioeconomic slice of women to a decline in these same women’s use of synthetic hormones often prescribed for menopausal symptoms. Breast cancer rates declined by as much as 10% annually in this group.

“This new research is seminal in that it throws light on a previously obscured variable.” says Dr. C. W. Randolph, Jr., “This demographic of women - white, educated and informed -is not only the segment of the female population most likely to stop using synthetic hormones, it is also the segment of women most actively embracing bioidentical hormone replacement therapies (BHRT) as a safe and effective alternative.”

After the published results of the 2002 Women’s Health Initiative (WHI) study unequivocally linked the use of synthetic hormone replacement drugs to an increased risk of breast cancers, heart attack, stroke and Alzheimer’s disease, millions of women decided to stop filling their prescriptions. Sales of the 2.2 billion dollar pipeline of synthetic hormones products, such as the popularly-prescribed Premarin and Prempro, soon plummeted by 50%. But according to Randolph, “The declining use of synthetic hormones is just one variable in this equation of decreased risk and the increasing popular choice of bioidentical hormone replacement therapies (BHRT) is the other.”

Read full article >>>

References:
- American Journal of Public Health First Look, published online ahead of print Feb 10, 2010

- Fournier, F. Berrino and F. Clavel-Chapelon, Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study, Breast Cancer Res Treat. 2008 January; 107(1): 103-111

- Seman, Barbara. The Greatest Experiment Ever Performed on Women. New York: Hyperion, 2003.